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Abstract
Cell fusion plays a well-recognized physiological role during development, while its function during progression is
still unclear. Here, we show that acute myeloid leukemia (AML) cells spontaneously fused with murine host cells
in vivo. AML cells fused in most cases with mouse macrophages. Other targets of AML cell fusion were dendritic
and endothelial cells. Cytogenetic and molecular analysis revealed that successive recipients conserved detectable
amounts of parental DNA. Moreover, in a mouse AML1-ETO model where female AML1-ETO–leukemic cells, ex-
pressing CD45.2, were injected in congenic CD45.1 male mice AML cells, we found hybrid cells expressing both
allelic types of CD45 and XXY set of sexual chromosomes. More importantly, the fusion protein AML1-ETO was
transferred in the hybrid cells. When sorted hybrid cells were reinjected in a secondary recipient, they gave rise to
leukemia with 100% penetrance and similar time of onset of leukemic cells. Our data indicate that in vivo fusion of
cancer cells with host cells may be a mechanism of gene transfer for cancer dissemination and suggest that fused
cells may be used to identify still unrecognized leukemogenic genes that are conserved in hybrid cells and able to
perpetuate leukemia in vivo.
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Introduction
The theory that cell fusion contributes to cancer progression was
introduced almost 100 years ago providing a non-mutational mech-
anism that could explain the aberrant gene expression pattern asso-
ciated with malignant cells (reviewed in [1–4]). It has been proposed
that cancer cells may fuse with different cell types including macro-
phages [5], stromal [6], epithelial [7], and endothelial cells [8,9]. In
solid tumors such as melanomas [10] and breast cancer [6,11], fusion
events have been proposed to play a possible role in cancer progres-
sion. The resulting hybrid cells were reported to be more aggressive
than their parental cells because of faster growth, acquisition of drug
resistance properties [12], higher propensity to metastasize, and dif-
ferent organotropism than the parental cells [13]. In addition, hy-
brids of myeloid and tumor cells expressed genes and differentiated
traits from both parental cells. This has been postulated to contribute
to immune escape [5]. Moreover, it has been recently reported that
hybrid cells derived from spontaneous fusion events exhibited stem
cell–like characteristics [14] and resulted in nuclear reprogramming
[15]. However, most of these studies reported spontaneous cell fusion
in vitro or the presence of hybrid cells in tumors in vivo, and the lack
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of a model where hybrid cells can be detected, subsequently isolated,
and eventually implanted in vivo has not allowed further studies on
gene transfer through cell fusion and its implications for tumor pro-
gression. In addition, these studies regarded essentially solid tumors
and there is no data suggesting a similar mechanism for leukemia.
While the manuscript was under review, Skinner et al. reported that
intra-hematopoietic cell fusion acts as a source of somatic variation in
the hematopoietic system [16], suggesting a putative role for increas-
ing tumor heterogeneity in leukemia.
Several cell fusion–associated molecules have been characterized.
Most of them are expressed on cell types that undergo cell fusion
in physiological processes, whereby some of them might also play a
role in tumor cell fusion such as the macrophage fusion receptor (also
known as SIRPα) and its ligands CD44 and CD47. Interestingly,
CD44 has been reported to play a role in leukemia initiation and
progression and targeting this receptor eradicates acute myeloid leu-
kemia (AML) in mouse models [17]. Moreover, it has been reported
that expression of CD44 variant exons in AML is more common and
more complex than that observed in normal blood, bone marrow
(BM), or CD34+ cells and that a strong expression of CD44-6v cor-
relates with shorter survival of patients with AML [18,19]. Expres-
sion of CD47 has been suggested to be an adverse prognostic factor
for patients with AML and the use of a CD47 antibody targeting
AML stem cells has been proposed for a possible therapeutic use
[20]. More recently, Theocharides et al. showed that disruption of
SIRPα signaling in macrophages eliminates human AML stem cells
in xenografts [21]. We speculate a putative role for SIRPα and its
ligands as a fusion mechanism.
We designed this study to investigate the role of cell fusion in
leukemia. Transplantation of human leukemias in NOD/Scid mice
successfully engrafts and faithfully recapitulates the pathology of the
original human leukemia. Weeks after injection, leukemia onset is
usually evaluated by expression of specific leukocyte markers, such
as human CD45 [21,22] on flow cytometry. This type of single spe-
cie analysis and the low frequency of hybrid cell events have probably
contributed to the misestimation of the cell fusion during leukemia
progression in the past. Moreover, the induction of mouse leukemia
by transplantation of transduced AML1-ETO leukemic cells in con-
genic mice allowed us to determine the fusion protein transfer from
the leukemic to the hybrid cell lending its leukemic potential.
We now report evidence for the malignant potential of hybrid cells
resulting from cell fusion of human primary and mouse leukemia
cells with host macrophages.
Materials and Methods
Collection of Patient Samples and Cell Lines
Peripheral blood (PB) and BM blood cells were collected from pa-
tients with newly diagnosed AML and acute lymphoblastic leukemia
(ALL) after obtaining informed consent. Individuals were diagnosed
with AML according to the standards of the World Health Organi-
zation classification. Patients’ samples were selected on the basis of
availability of materials and cells from 14 different samples represent-
ing five AML subtypes, and five ALL cases were investigated for
in vivo studies. Detailed characteristics of the patients included in
this study are shown in Table W1. Cells were separated using Biocoll
Separating Solution (Biochrom AG, Berlin, Germany) to obtain a
mononuclear cell population, washed in RPMI 1640 (EuroClone,
Milano, Italy) supplemented with 10% FBS (Gibco-Invitrogen, Life
Technologies, Carlsbad, CA), and counted. Cells were then washed
and freshly inoculated into mice or otherwise frozen in FBS plus
10% CryoSure-DMSO (WAK-Chemie Medical GmbH, Steinbach,
Germany) and stored in liquid nitrogen. As controls, umbilical cord
blood CD34+ cells were immunomagnetically purified with a CD34
microbead kit (Miltenyi Biotec, Bergisch Gladbach, Germany) ac-
cording to the manufacturer’s instructions. HL60, KG-1 AML lines,
MOLT-16, and 697 ALL lines were used in this study, cultured
according to the bank’s protocols, and purchased at DSMZ Bank
(Braunschweig, Germany).
Mice and Human Leukemia Transplants
NOD/LtSz-Prkdcscid (NS), NOD.Cg-PrkdcscidB2mtm1Unc (NSB),
and NOD.cg-PrkdcscidIl2rgtm1Wjll (NSG) were kindly donated by
Dr L. Shultz, bred, and housed at Charles River Laboratories (Calco,
Italy). The following mice strains were obtained from Charles River
Laboratories: C57B6/J (C57-CD45.1) and B6.SJL-Ptprca Pep3b/
BoyJ (C57-CD45.2). All animals used were in a range of 6 to 8 weeks
old. Experiments involving animals were done in the animal facilities
at Istituto FIRC di Oncologia Molecolare (IFOM)-Istituto Europeo di
Oncologia (IEO) campus (Milan, Italy) and all procedures were carried
out in accordance with national and international laws and policies. For
induction of AML-like leukemia, 1 × 107 low-densitymononuclear cells
from the BM of newly diagnosed AML patients were injected intra-
peritoneally (ip) in non-irradiated mice. Human engraftment was
defined bymeans of percentage humanCD45+ cells in PB from tail vein
of the recipient animals. Mice were checked periodically for signs of
disease (ruffled fur coat and hunched back), for complete blood cell
count, and for the presence of blast cells by May-Grünwald-Giemsa
staining of blood smears. Flow cytometry analyses were performed for
the first time a month after transplant and repeated every month. When
engraftment rose 50% hCD45+ cells, animals were monitored daily and
blood sampling and subsequent fluorescence-activated cell sorting (FACS)
analysis was performed every week until mice were sacrificed. Secondary
transplants were performed by injecting spleen or BM cells of primary
transplanted mice and successively in secondary and tertiary recipients.
Generation of Mouse Models of AML1-ETO Leukemias
Lin− cells were purified with a lineage cell depletion kit (StemSep
Mouse Hematopoietic Progenitor Cell Enrichment Kit; Stem Cell
Technologies, Vancouver, Canada) according to the manufacturer’s
instructions from the BM of C57-CD45.2 female mice. Briefly, after
centrifugation through a Ficoll gradient, mononucleate cells were
enriched for progenitors by negative selection of cells presenting
myeloid, erythroid, and lymphoid differentiation markers. Unwanted
cells are targeted for removal with biotinylated antibodies directed
against non-hematopoietic progenitor cells [CD5 (Ly-1), CD11b
(Mac-1), CD45R/B220, Ly-6G/C (Gr-1), neutrophils (7-4), TER119]
and tetrameric antibody complexes recognizing biotin and dextran-
coated magnetic particles. Labeled cells are then separated and StemSep
Columns and Magnets. Flow-through containing Lin− cells was
collected, centrifugated, and resuspended in medium containing
interleukin-3, interleukin-6, and stem cell factor for 36 hours in a cell
incubator. Cells were then plated onto retronectin-coated (Takara-
Shuzo, Shiga, Japan), non-tissue culture-treated plates and exposed to
the supernatant of packaging, ecotropic Phoenix cells transiently trans-
fected with the PINCO–AML1-ETO retroviral vector as previously
described [23]. Transduced cells were sorted using a BD FACS Vantage
instrument and iv injected into lethally irradiated C57-CD45.2
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female mice. Four weeks later, mice were treated with a single dose of
N -ethyl-nitrosourea (Sigma-Aldrich, St Louis, MO; 50 mg/kg, ip).
The animals develop myeloblastic leukemia with a latency of 20 weeks
as previously described [23]. Leukemic spleens were then dissociated
and reinjected ip at different doses into lethally irradiated C57-
CD45.1 male mice. Recipient mice were checked periodically for signs
of disease, for complete blood cell count, and for the presence of blast
cells by May-Grünwald-Giemsa staining of blood smears. Leukemia
burden was detected in the PB by the presence of CD45.2+ cells by
cytometry analyses repeated every 2 weeks. Secondary transplants were
performed injecting spleen or BM cells of primary transplanted mice
and successively in secondary recipients.
Antibody Blocking Experiments
Whole IgG or F(ab′)2 fragments of clone IM7.8.1 (ATCC,
Rockville, MD), a rat IgG2B monoclonal antibody recognizing all
human and mouse isoforms of the CD44 expressed on hematopoietic
cells, were ip injected at a dosage of 750 or 500 μg, respectively, per
injection three times a week, for 4 weeks, into mice transplanted with
AML cells 10 days earlier. As isotype control (IgG2b), an antibody to
CD8, clone 2.43 (ATCC), was injected with the same schedule.
Anti-human CD47 antibody, B6H12.2 (ATCC), was given daily
at a dosage of 100 or 50 μg by ip injection for 4 weeks into mice
transplanted with AML cells 3 days earlier. An IgG1 antibody against
Myc (9E10; Santa Cruz Inc, Capitola, CA) was injected at the same
dose in control mice.
Flow Cytometry
Leukocytes from PB, spleen, and BM were isolated by mechanical
dissociation of the organs, filtered on a 40-μm cell strainer, and ana-
lyzed by four- or six-color analysis as previously described [22]. For
human AML engraftment evaluation, cells were previously incubated
with CD16/CD32 (2.4G2) and then incubated with anti-human
CD45 (clone 2D1), anti-mouse CD45 (30-F11), or with the follow-
ing antibodies: for human antigens—anti-CD34 (8G12), anti-CD33
(P67.6), anti-CD13 (WM15), anti-CD31 (WM59), anti-CD14
(M5E2); for murine antigens—anti-CD45 (30-F11), anti-VEGFR2
(AVAS12a1), anti-CD11b (M1/70), anti-CD11c (HL3), anti-Gr-1
(RB6-805), anti–Sca-1 (D7), anti–Ter-119, anti-CD117 (2B8). These
antibodies were purchased from BD Bioscience Pharmingen Inc
(San Diego, CA). Anti-mouse CD11b (5C6) from Abcam (Cambridge,
United Kingdom) was also used.Mouse AML engraftment evaluation was
performed by flow cytometric analysis of CD45.1 and CD45.2 mouse
isotypes; anti-CD45.1 (clone A20) and CD45.2 (clone 104) antibodies
were from eBioscience (San Diego, CA). Apoptotic cells were depicted
and excluded from the analysis by 7AAD staining (Sigma-Aldrich). DNA
content was measured by propidium iodide staining as described else-
where and analyzed by flow cytometry in a BD-FACScan flow cytometer.
Cell sorting experiments were performed in a BD-FACSAria cell
sorter platform. Dead cells were excluded by a combination of scatter
gates, and doublets were eliminated using the pulse-width parameter.
Immunohistochemistry
Immunostaining for human and murine antigens was performed
on serial sections of formalin-fixed and paraffin-embedded biopsies
with an automated immunostainer (Autostainer; Dako, Glostrup,
Denmark), using a commercial detection kit (Dako EnVision Plus-
HRP; Dako), according to the manufacturer’s instructions. Antigen
retrieval was obtained by placing tissue sections in 0.01 M EDTA
buffer at pH 8.0 and underwent three cycles at 90°C in a microwave
oven operating at 780W as previously described [24]. Negative control
sections were incubated with non-immune mouse serum in place of the
specific primary antibodies and consistently lacked any staining. Myelo-
peroxidase cytochemical staining in blood smears was performed with a
commercial kit (Sigma Aldrich) following manufacturer’s instructions.
Fluorescence In Situ Hybridization
To better characterize the hybrid phenotype of fused cells, we per-
formed fluorescence in situ hybridization (FISH) on BM and spleen
cells as previously described [25]. For BM experiments, animals were
treated with 200 μl of KaryoMAX Colcemid (Gibco, Invitrogen
Corporation) ip injected for 1 hour before sacrifice. For FISH experi-
ments, cell suspensions obtained from spleen dissociation were
treated with KaryoMAX Colcemid for 45 minutes. Cell suspension
were treated with hypotonic solution (KCl, 0.075 M) and fixed in
methanol/acetic acid. Chromosome spreads and interphase nuclei
were hybridized in situ with mouse Cot-1 DNA and BAC RP23-
403C21 (for murine X chromosome) labeled with Cy3 (Amersham
Biosciences, GE Healthcare, Buckinghamshire, United Kingdom)
and with human cot-1 DNA and BAC RP4-567G7 (for murine Y
chromosome) labeled with FluorX (Amersham Biosciences) by nick
translation as described previously [25]. The commercial probe LSI
ETO SpectrumOrange/AML1 SpectrumGreen dual color (Abbott
Molecular Inc, Des Plaines, IL) was used for the presence of the
fusion gene. Chromosomes and interphase nuclei were counterstained
with 4′,6-diamidino-2-phenylindole (DAPI). Digital images were ob-
tained using a SkyVision workstation (Applied Spectral Imaging,
Migdal Ha’Emek, Israel).
DNA Extraction and Polymerase Chain Reaction Analysis
High–molecular weight DNA was extracted from the PB, the
spleen, and the BM of each mouse by the Dneasy Blood and Tissue
Kit (Qiagen GmbH, Hilden, Germany). The presence of human-
specific DNA within the BM or the spleen of transplanted mice
was confirmed by polymerase chain reaction (PCR) of the human spe-
cific Alu sequence [26]. The amplification fragments were detected
using the forward primer 5′CACCTGTAATCCCAGCACTTT and
the reverse primer 5′CCCAGGCTGGAGTGCAGT. The reaction
was performed in a final volume of 50 μl using 0.5 U of AmpliTaq
Gold (Applied Biosystems, Carlsbad, CA), 250 nM of each primer,
0.4 mM of each nucleotide, and 25 mM MgCl2. Following an initial
DNA denaturation at 94°C for 2 minutes, thirty-five 1-minute cycles of
denaturation at 94°C, 1-minute annealing at 55°C, and 1-minute ex-
tension at 72°C were performed before a final elongation step at 72°C
for 7 minutes. For the PCR of chromosome 17, amplification of an
850-bp fragment was detected using the forward primer 5′GGGATA-
ATTTCAGCTGACTAAA and the reverse primer 5′TTCCGTTT-
AGTTAGGTGCAGTTATC. The reaction was performed using a
Taq PCR Master Mix (Qiagen GmbH) with 250 nM primer concen-
tration. Following an initial DNA denaturation at 94°C for 2 minutes,
thirty-five 45-second cycles of denaturation at 94°C, annealing at 60°C,
and extension at 72°C were performed before a final elongation step at
72°C for 7 minutes. All amplified DNA fragments were stained with
SybrSafe DNA gel stain (Invitrogen Corp), electrophoresed through
1% agarose gel, and visualized in UV light. As an internal control,
the presence of the glyceraldehyde-phosphate dehydrogenase
(GAPDH) housekeeping gene was analyzed using the human/mouse
GADPH primer set (Millipore, Billerica, MA).
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Results
Human AML Cells Form Hybrid Cells with
Murine Cells In Vivo
We injected non-irradiated NSB mice ip with 1 × 107 AML cells
from 14 AML patients (for details, see Table W1). Human leukemia
engraftment was first evaluated as the presence of human CD45+
cells by flow cytometry in BM, PB, and spleen. Data regarding the
species specificity of anti-human and anti-murine monoclonal anti-
bodies used are provided as supporting information (Figure W1). In
addition, non-specific binding in cell mixing experiments in which
human leukemia and mouse PB cells were mixed and then stained
with human and mouse antibodies are shown as supporting informa-
tion (Figure W2). Human leukemia was developed in 75.8% of mice
with a latency range of 4 to 16 weeks. In most cases, human engraft-
ment was detected by the presence of human CD45+ cells (Figure 1A,
left panel ), and in some cases, leukemia do not engraft (Figure 1A,
right panel ). However, in mice injected with cells derived from three
different AML cases (Q-IEO, So-IEO, and Ga-IEO), we observed
that a well-defined cell population of about 0.3% to 5% of the
human leukemic cells also co-expressed the murine CD45 antigen
(Figure 1A, central panel, Q-IEO; Figure 1B, So-IEO and Ga-IEO).
At sacrifice, fused cells were observed in three cellular compartments
(PB, BM, and spleen; Figure W3). After fusion, most of the cells shar-
ing human and murine CD45 antigens showed a murine myeloid
(CD11b/CD33/CD14-positive) phenotype, suggesting that hybrids were
from human leukemic cells and murine macrophages (Figure 1B).
Human leukemic cells of these three patients did not express CD11b
(Table W1), and the absence of non-specific binding in cell mixing
experiments of human leukemia and mouse PB cells is shown as sup-
porting information (Figure W2).
Human and Mouse DNA Are Detectable in Hybrid Cells
and Hybrid Cells Are Leukemogenic
Human engraftment was evaluated by PCR analysis for the α-satellite
region of human chromosome 17. PCR products performed in differ-
ent groups of serial transplanted mice showed human engraftment in
several of the primary and secondary recipients but not in all the tertiary
and quaternary recipients nor in the DNA of a healthy mouse used as a
control (Figure 2C , upper panel ). To detect small amounts of genomic
DNA transferred, we took advantage of the species-related specificity
Figure 1. Human AML cells fuse with mouse CD11b–positive macrophages in vivo. (A) Flow cytometry analysis of PB from a represen-
tative leukemic mouse without cell fusion events (left panel), a leukemic mouse showing human engraftment (Q-IEO) and hybrid cells
(0.5%, center), and from mouse without human engraftment (right panel). (B) Flow cytometry analysis of different AML showing distinct
population of hybrid cells. (C) Flow cytometry analysis ofmouse PB showing amyeloid leukemic population expressing human CD45, CD33,
and CD14, as well as murine CD11b.
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and of the highly repetitive Alu sequences to perform a sensitive and
specific quantification of human genomic DNA by PCR analysis. A
PCR product was detected in all recipient leukemic mice but not in
the DNA of a healthy mouse used as a control (Figure 2C , middle
panel ). PCR detection of the GAPDH human/mouse housekeeping
gene confirmed that a comparable amount of DNA was amplified in
the above-described PCR experiments (Figure 2C , lower panel ).
FISH analysis labeling human and murine Cot-1 DNA with the
same efficacy-specific hybridization probes showed the concomitant
presence of both human and murine genomic content in cell inter-
phases of cells from recipient mice (Figure 2A). Although spon-
taneous metaphases were rare in these cytogenetic preparations and
small fragments of genomic DNA were difficult to visualize with the
cot-1 labeling, Figure 2B shows a complete mouse karyotype with two
additional human chromosomes observed in cells from a spleen of
patient Q-IEO recipient mouse. Taken together, these results suggest that
human DNA was transferred to the hybrid human/murine AML cells.
To investigate the leukemic potential of hybrid cells, we sorted
human CD45/mouse CD45 double-positive cells from five BMs of
leukemic xenotransplanted mice and injected them in secondary recip-
ient. The sorting strategy was design to first discard dead cells and
deplete cell doublets. Human CD45+ cells and hybrid human CD45+/
mouse CD45+ cells were then separated by cell sorting with a purity of
93.1% and 90.2%, respectively (Figure W4). Hybrid cells promoted
leukemia with a time of onset similar to human AML cells (40 vs 46 days
for animals injected iv with 2 × 105 cells hCD45/mCD45 or hCD45,
respectively). At sacrifice, the percent of human engraftment of ani-
mals that received human leukemic cells was similar to that of animals
that received sorted fused cells (82–85% in the PB, 93–95% in the
BM, and 95–98% in the spleen of human CD45+ leukemic cells).
The presence of fused cells was detected in all the recipients in a variable
ratio of 0.1% to 7% human CD45/mouse CD45 positive cells.
The Cell Fusion Occurs in a Murine Model of AML and the
Gene AML1-ETO Can Be Transferred to the Hybrid Cells
Conferring Leukemogenic Potential
The absence of chromosomal aberrations or known fusion pro-
teins in the three human AML cases of this study made difficult
Figure 2. Human DNA content is detectable in hybrid cells. (A) Dual-color FISH of interphase nuclei showing co-localization of mouse
(FluorX–mcot-1 DNA) and human (Cy3-hcot-1 DNA) genomic DNA content in cells from spleen of a secondary recipient. (B) Dual-color
FISH of a metaphase spread from a spleen cell of a tertiary recipient containing mouse (Cy3–mcot-1 DNA) and human chromosomes
(FluorX–hcot-1 DNA) and counterstained with DAPI. Arrows, human chromosomes. (C) PCR analysis of human engraftment of spleen
cells of three representative series of transplanted mice. PCR analysis of DNA of α-satellite region of chromosome 17 (upper row) and
human Alu-specific sequences (medium row) detecting human DNA content in serial mouse recipients. Lower row, PCR detection of
the GAPDH housekeeping gene confirmed that the same amount of DNA was amplified in PCR experiments. F, recipient (F1, primary;
F2, secondary; F3, tertiary; and F4, quaternary recipient); H, human DNA of a healthy donor; M, mouse DNA of a healthy mouse.
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the determination of putative leukemic gene transferred from human
to hybrid cells. To further study the mechanism of DNA transfer
from cancer to normal cells, we decided to analyze whether the
AML1-ETO leukemic gene, which can be followed as a cytogenetic
alteration, should be transfer to hybrid cells in vivo in an AML
murine leukemia model. C57-CD45.1 male mice were injected with
leukemic murine cells from C57-CD45.2 donor female mice. Immuno-
phenotype of AML1-ETO CD45.2 leukemia was analyzed. As re-
ported in Figure W5, 1.8% of the Lin− population expressed Sca1
and cKit. When mice were overtly leukemic, their BM, PB, and spleen
were investigated by flow cytometry for the expression of both allelic
isoforms CD45.1 and CD45.2. About 4% to 6% of BM cells expressed
both CD45.1 and CD45.2 antigens, suggesting that also in this AML
mouse model fusion events might occur (Figure 3A). Non-specific
staining of CD45.1 and CD45.2 antibodies on both single staining
and mixing cell staining experiments of PB from C57-CD45.1 and
C57-CD45.2male mice was excluded as shown in FigureW6. Immuno-
fluorescence staining and image analysis confirmed the presence of
cells that co-express CD45.1 and CD45.2 antigens (Figure 3B).
CD45.1/CD45.2 double-positive cells were then isolated by cell sort-
ing from the spleen of leukemic mice. Sorting strategy involves discard-
ing dead cells and doublets as shown in the upper panels of Figure 3A.
Sorted CD45.1/CD45.2 double-positive cells were then investigated
by FISH analysis. As shown in Figure 4, A and B, a cell population
carried two X and one Y chromosome set providing evidence of their
hybrid origin, from the donor and the recipient mice. Furthermore, in
sorted CD45.1/CD45.2 double-positive cells, the presence of AML1-
ETO fusion protein was detected in cells with the Y chromosome
(Figure 4C), suggesting that fusion can be a mechanism for the transfer
of leukemic genes to donor normal cells. Interestingly, sorted CD45.1/
CD45.2 double-positive cells (purity 91.07%) reinjected at different
doses in recipient animals promoted leukemia with a kinetics similar
to CD45.2 AML1-ETO leukemic cells (purity, 98.8%), 21 versus
24 days of latency for three animals injected with 106 cells and 23.8
versus 21.6 for six animals injected with 105 cells (CD45.1/CD45.2
or CD45.2, respectively).
AML Cells Can Fuse also with Endothelial and Dendritic Cells
To further investigate what type of mouse cells fuse with the human
leukemic cells, we analyzed BM of leukemic mice by flow cytometry.
In addition to macrophages, some human AML cells formed hybrids
also with dendritic (i.e., CD11c-positive; Figure 5A, upper panels) or
Figure 3. AML1-ETO AML cells expressing CD45.2 fuse with CD45.1 cells from host mice. (A) Flow cytometry analysis of a leukemic
spleen for the expression of both allelic isoforms CD45.1 and CD45.2 showing three different populations: CD45.2+ cells were AML1-
ETO–engrafted cells, CD45.1 were host cells, and cells with both allelic isoforms CD45.1 and CD45.2 were hybrid cells. Left upper
panels show discarding of dead cells and doublets. Lower panels show sorted CD45.2 cells at 98.8% purity and CD45.2-CD45.1 double-
positive cells at 91.1% purity. (B) CD45.2–PE-Cy5 (red) and CD45.1–fluorescein isothiocyanate (green) double immunofluorescence staining
on BM cells confirmed the presence of cells that co-express both antigens (merge). Immunostaining was performed on cells analyzed in
Figure 3A, and cells were counterstained with DAPI.
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endothelial (CD45-negative, Flk-1–positive; Figure 5A, lower panels)
murine cells.
AML and ALL but Not CD34+ Cord Blood Cells Promoted
Cell Fusion
Acute leukemia cell fusion was not AML-type restricted, because it
was observed after the ip injection of different AML FAB types (M1,
M4, M5) or AML cell lines (HL60, KG1; Figure W6A) and also
after the ip injection of ALL-B and ALL-T (Figure 5B) primary cells
or cell lines (MOLT-16, 697; Figure W7A). In contrast, from the
injection of CD34+ cells isolated from cord blood, we did not obtain
fused cells in neither primary nor secondary recipients (Figure 5C ),
suggesting that fusion ability might be a characteristic of tumor cells.
Human leukemia cell fusion was not restricted to a specific NS-
related strain. In fact, fusion events were observed by flow cytometry
in BM samples of NS, NSB, and NSG mice, albeit at different
frequencies (ranging from 0.2% to 11% of human AML cells in pri-
mary recipients; Figure W7B).
Monoclonal Antibodies Directed against CD44 or CD47
Do Not Inhibit Specifically AML Cell Fusion
It has been reported that targeting of CD44 eradicates human
AML leukemic stem cells [17]. IM7 is a biologically active anti-
CD44 antibody and it has been shown that treatment with this
antibody inhibits BCR-ABL blast engraftment and subsequent
chronic myeloid leukemia (CML)-like myeloproliferative disease
(MPD) development in mice. In our hands, administration of
IM7 induced systemic shock and death (data not shown), but its
F(ab′)2 fragments did not induce a reaction in mice. However, treat-
ment of AML-transplanted mice with these F(ab′)2 fragments did not
have any effect on human engraftment in terms of time of onset of
the leukemia symptoms and percent of human cells in PB, spleen,
and BM at mice sacrifice. Blocking CD44 neither modified signifi-
cantly the percent of fusion events obtained in PB and BM at sacrifice
of 10 mice in two different experiments (Figure W8A).
In contrast, administration of the anti-CD47 monoclonal anti-
body B6H12.2, used either at 100 or 50 μg/mouse daily 3 days after
AML transplant, completely prevented AML engraftment in spleen
(91% of human cells in isotype Ig control–treated mice vs 0% of
anti–CD47-treated animals), BM (53% vs 0%), and PB (59% vs 0%),
thus hampering the detection of any fusion event. In some experiments,
the administration of anti-CD47monoclonal antibody (mAb) was inter-
rupted after 4 weeks of treatment, and 4 months later, human engraft-
ment was measured in the PB. Complete absence of human CD45+ cells
(Figure W8B) suggested that the inhibition of CD47 targeted also can-
cer stem cells in these AML cases. Importantly, a very recent work while
this paper was under review, reported that disruption of SIRPα signaling
in macrophages eliminates AML stem cells in xenografts [21], as we
suggest from our secondary transplants of anti–CD47-treated mice.
Discussion
Our data provide novel evidence that human and murine leukemic
cells may spontaneously fuse in vivo with mouse normal cells result-
ing in hybrid cells containing DNA and protein markers from both
Figure 4. FISH analysis of sorted CD45.1/CD45.2 double-positive cells. (A, B) Dual-color staining of X (FluorX; green) and Y (Cy3; red)
chromosomes counterstained with DAPI. (C) Dual-color staining of AML1-ETO fusion protein (ETO SpectrumOrange/AML1 Spectrum-
Green; AML1-ETO fusion protein; yellow) and Y (Cy3; red) counterstained with DAPI.
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fusion partners. None of the human cases examined presented abnor-
mal cytogenetic characteristics and it was not possible to follow the
putative “leukemic” gene transferred from human to mouse cells.
However, the mouse model of AML1-ETO leukemia allowed us to
confirm that hybrid cells contained the leukemia-generating AML1-
ETO fusion protein. When transplanted in a secondary recipient,
these hybrids were capable to transfer leukemia in vivo. Our data in-
dicate that tumor cell fusion might be a mechanism of gene transfer
for leukemia dissemination and suggest that further studies on the
screening of human genes in hybrid cells can be a useful tool in the
identification of new human genes involved in leukemia.
Most of the hybrid leukemic cells were CD11b-positive. One of
the main functions of macrophages is internalization of apoptotic cells,
pathogens, and foreign bodies and their routing toward lysosomes for
degradation. However, macrophages have alternative internalization
pathways toward homotypic fusion with other macrophages, leading
to multinucleation. Thus, abortive digestion of tumor cells might be
a potential mechanism for hybrid formation [2,3]. Macrophage cell
fusion can be mediated by CD44 and its occupancy prevents multi-
nucleation [27]. It has also been reported that targeting CD44 with
the activating antibody H90 inhibits engraftment of human AML
in vivo [17]. Here, we presented the data obtained with another
CD44 antibody, IM7 (reported to be able to inhibit BCR-ABL engraft-
ment [28]), showing no effect on AML engraftment. These data sug-
gest that different epitopes of CD44 might play different roles on
leukemia cell homing and engraftment and do not exclude a CD44
involvement in AML fusion events and successive engraftment. CD47
is another ligand for macrophage fusion receptor (MFR)/SIRPα that
participates in macrophage multinucleation, and its expression has been
reported to be an adverse prognostic factor in patients with AML [20].
Weissman’s group showed that targeting CD47 with the monoclonal
antibody B6H12.2 inhibits AML engraftment by increasing phago-
cytosis of cancer cells [20]. The same group recently reported that
CD47 is overexpressed and acts as an anti-phagocytic signal in tumor
cells, contrasting and so regulating the function of calreticulin [29].
Calreticulin is only highly expressed in tumor cells and the antibody
anti-CD47 is able to elicit phagocytosis only in tumor cells that express
calreticulin [29]. The reason why tumors cells should express a pro-
phagocytic signal in the cell surface is not fully understood and we spec-
ulate a possible involvement of the CD47-calreticulin balance on cell
fusion. However, when we treated AML-transplanted mice with the
CD47 antibody at different doses, the complete inhibition of AML
Figure 5. Human AML cells fuse also with dendritic and endothelial cells. (A) Upper panels show flow cytometry analysis of cells co-
expressing human CD45, CD33, and CD14 that express also murine CD11c, a dendritic cell–specific marker. Lower panels show flow
cytometry analysis of mouse endothelial cells (Flk-1–positive) expressing human CD45 and human CD31. (B) In addition to AML, ALL cell
transplantation induces cell fusion in vivo; 1 × 107 primary human ALL cells were injected ip, and 47 ± 6 (ALL-B) or 72 ± 13 (ALL-T) days
later, animals were sacrificed and spleen cells were analyzed by flow cytometry for the co-expression of human and mouse CD45.
(C) Human CD45 and mouse CD45 flow cytometry expression patterns of BM cells from a primary and a secondary recipient of human
cord blood CD34+ cells showing absence of hybrid cells.
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engraftment prevented any fusion event. Further experiments to inves-
tigate the role of calcericulin-CD47 in cell fusion should be addressed
in future studies.
Cancer cell fusion with macrophages or stroma cells might induce
immune escape [2,6]. Now, we present evidence that some human
AML cells fuse also with endothelial (CD45-negative, Flk-1–positive)
murine cells. It has been suggested that through fusions with endo-
thelial cells, cancer cells may temporarily or permanently acquire
endothelial cell characteristics that enhance their capability to traverse
the endothelial barrier and metastasize [8].
Past studies about individual X-chromosome inactivation pattern
(XCIP)–related clonality in AML have failed to identify multiple
clones of the disease. However, there is recent evidence of XCIP skew-
ing (>75% expression of one allele) occurring in a large proportion of
hematologically normal females, probably because of the stem pool
size at the time of lyonization. Moreover, limits in the sensitivity of
the procedures used to assess clonality through XCIP may hamper the
detection of small subclones [30], particularly considering that our
data show a very small window of contemporary presence of the full
genome of cancer and healthy host cells. In addition, a recent study
has found the presence of apparently non-clonal AML foci in the
spleen of some patients [31].
Fusion between cancer and normal cells can generate genomic and
epigenetic variability at a rate exceeding that achievable by random
mutagenesis [32]. This suggests a new possible use of our in vivo
model. Thus, one can speculate that human cancer-inducing genes
are “enriched” in hybrids between human leukemia and host murine
cells (Figure W9). According to this working hypothesis, hybrid cells
able to transfer leukemia to host mice are a particularly interesting
target for screening of human cancer–driving genes.
Our findings offer new insight into a number of still unresolved
clinical questions. Fusion of cancer cells with stroma (macrophages
and endothelial cells) may explain cancer recurrence after therapy in
patients who achieved a remission and had no morphologic or molec-
ular evidence of residual disease. In fact, the expression of CD11b
(a human macrophage marker), in the presence of progenitor cell–
related markers and in the absence of markers of differentiation along
the monocytic lineage, has been found to be a negative prognostic
factor in human AML [33]. Likewise, cell fusion can explain enigmas
such as BM cell–derived gastric cancer [34], the observation of donor
cell–derived cancer [4] or leukemia [35] in recipients of allogenic BM
transplants, the presence at leukemia relapse of clones different from
those observed at diagnosis [36], the presence of cancer-specific genetic
aberrations in the endothelial cells of some cancer vessels [9], the presence
of a stem cell–like population of ALL cells co-expressing EC markers
[37], and on a more general basis, the observed correlation between
chronic inflammation (wheremacrophages play a crucial role) and tumor-
igenesis [3,4]. Overall, our data indicate, for the first time to our knowl-
edge, that leukemia cells fuse with stromal cells in vivo and the malignant
potential of the leukemia cell is maintained in the resulting hybrid cells.
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Figure W1.Monoclonal antibodies used in this study were unambiguously species specific. mAbs to human CD45, CD13, CD33, CD14,
and CD31 do not bind mouse PB cells. mAbs to mouse CD45 and CD11b do not bind human leukemic cells.
Figure W2. Doublets can be excluded by physical parameters and mouse CD45 and CD11b and human CD13, CD33, and CD45 recognize
mouse PB cells and human leukemic cells, respectively.
Figure W3. Hybrid human CD45+–mouse CD45+ cells are detected in PB, BM, and spleen of leukemic mice after human AML transplant
of three patients (Q-IEO, n = 17; So-IEO, n = 11; Ga-IEO, n = 12).
Figure W4. Cytofluorimetric analysis of c-Kit expression on a cell population of Lin−Sca-1+ cells of a spleen of a mouse with AML1-ETO–
induced leukemia.
Figure W5. Doublets can be excluded by physical parameters and antibodies to mouse CD45.1 and CD45.2 selectively recognize two
different cell populations in a mixed sample of PB from C57-CD45.1 and C57 CD45.2 mice.
Figure W6. Sorting strategy to isolate human CD45– and mouse CD45–positive cells. An appropriate gate to exclude putative doublet
formation allows us to sort only hybrid cells expressing hCD45 and mCD45.
Figure W7. Cell fusion is a common event in different mouse strains during AML development and is not restricted to NSB mice.
(A) Evaluation of engraftment (percent of hCD45+ cells) and frequency of fusion events of AML and ALL cell lines on NS, NSB, and
NSGmice. (B) Flow cytometric analysis of human CD45 andmouse CD45 expression of BM samples frommice injected with HL60, KG-1,
MOLT-16, and 697 AML cell lines into NSB mice.
Figure W8. Targeting CD44 or CD47 does not inhibit specifically AML cell fusion. Engraftment evaluation by cytofluorimetric analysis of
hCD45 staining. Mice (n= 3), samples 1 to 3, treated with anti-human CD47 antibody (50 μg, ip, daily for 4 weeks) do not show presence
of human leukemic cells in comparison with mice treated with isotypic matching IgG1 (control, upper panels). Engraftment evaluation by
cytofluorimetric analysis of CD45.2 staining. Mice treated with isotypic matching IgG2b (control, upper panels) and mice (samples 1–3)
treated with F(ab′)2 fragments of anti-CD44 (500 μg, ip, three times a week, for 4 weeks) do not present differences in terms of per-
centage engraftment and cell fusion events.
Figure W9. Our working hypothesis on AML cell fusion (schema depicting the potential mechanism by which gene transfer by cell
fusion can play a role during leukemogenesis): AML cells (blue cells, containing leukemic DNA represented as a red chromosome) fuse
with host cells (white cells) generating hybrid cells with different genomic content. These hybrid cells might represent a reservoir to
develop leukemia.
